Alector Inc's collaboration with AbbVie on the AL002 TREM2 program for early Alzheimer's disease has been terminated after the clinical trial did not meet its primary endpoint, ending their agreement.
AI Assistant
ALECTOR INC
2025
8 K
Find Answers
Ask about any part of the document to get insights, explanations, or key details.